Zevra Therapeutics (ZVRA) Acquisitions (2023)
Zevra Therapeutics' (ZVRA) quarterly Acquisitions came in at $30.4 million in Q4 2023, up 115.98% on a QoQ basis from $14.1 million in Q3 2022.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Acquisitions (2023) Analysis & Trends
Zevra Therapeutics (ZVRA) has 2 years of Acquisitions data on file, last reported at $30.4 million in Q4 2023.
- Quarterly Acquisitions changed N/A year-over-year to $30.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $44.5 million (up 215.98% YoY) and the FY2023 annual result came in at $30.4 million, up 115.76% from the prior year.
- Acquisitions improved to $30.4 million in Q4 2023, from $14.1 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $30.4 million in Q4 2023 to a low of $14.1 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | - |